Rep. Byron Donalds Sells Off Shares of Novo Nordisk A/S (NYSE:NVO)

Representative Byron Donalds (R-Florida) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on March 20th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Gartner (NYSE:IT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Equifax (NYSE:EFX) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Tradeweb Markets (NASDAQ:TW) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 3/20/2025.

Novo Nordisk A/S Stock Down 7.1 %

Shares of Novo Nordisk A/S stock traded down $4.45 during trading hours on Thursday, reaching $58.43. 23,528,479 shares of the company’s stock were exchanged, compared to its average volume of 5,920,889. The company has a 50 day moving average of $76.55 and a two-hundred day moving average of $92.55. The stock has a market cap of $262.22 billion, a P/E ratio of 17.75, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a fifty-two week low of $57.36 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 49.54%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday. They set an “underperform” rating on the stock. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $135.00.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Center for Financial Planning Inc. lifted its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its holdings in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Transce3nd LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $39,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.